SELLAS rises as Q1 update suggests lead program nears final analysis
Source: SeekingAlpha
2026-05-13 07:12:27 ET
More on SELLAS Life Sciences
- Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event
- Sellas Life Sciences: Behind The Big Surge
- Sellas Life Sciences: REGAL Study Results Due Any Day Are A Major Potential Upside Catalyst
- SELLAS Life Sciences GAAP EPS of -$0.05 beats by $0.01
- Seeking Alpha’s Quant Rating on SELLAS Life Sciences
Read the full article on Seeking Alpha
For further details see:
SELLAS rises as Q1 update suggests lead program nears final analysis
SELLAS Life Sciences Group Inc.
NASDAQ: SLS
SLS Trading
20.38% G/L:
$6.97 Last:
7,820,479 Volume:
$6.48 Open:
SLS Latest News
May 12, 2026 04:05:00 pm
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
March 19, 2026 04:05:00 pm
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
SLS Stock Data
$535,597,063
140,448,048
1.12%
50
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
